Generate Biomedicines, Inc.
About Generate Biomedicines, Inc.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $7.2M
- Net income
- -$61.4M
- Total assets
- $625.7M
- Market cap
- $1.6B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- Shares outstanding
- 129.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 27, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $61.4M in FY2026.
- Trading 21% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Generate Biomedicines, Inc..
Write a review
News about Generate Biomedicines, Inc.
News & sentiment via Polygon.io
